Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?
07:41am, Wednesday, 15'th Mar 2023
Mirati (MRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference
04:30pm, Monday, 06'th Mar 2023
SAN DIEGO , March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14
Mirati Therapeutics, Inc. (MRTX) Q4 2022 Earnings Call Transcript
10:29pm, Tuesday, 28'th Feb 2023
Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Ryan Asay - VP of Corporate Affairs David Meek - CEO Charles Baum - Presiden
Mirati (MRTX) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 28'th Feb 2023
Mirati (MRTX) delivered earnings and revenue surprises of 6.15% and 75.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Technical Pressure Could Drag Biotech Lower
01:24pm, Monday, 13'th Feb 2023
The shares of Mirati Therapeutics Inc (NASDAQ:MRTX) have been pulling back on the charts this month, after running into the $55 level.
Mirati Therapeutics: Suddenly A Battleground Stock
02:51pm, Wednesday, 08'th Feb 2023
Today, we take a deeper look at mid-cap oncology name Mirati Therapeutics for the first time in several years. The company's first FDA approval and some other positive milestones have been overshadowe
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
10:50pm, Monday, 09'th Jan 2023
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:30pm, Thursday, 22'nd Dec 2022
SAN DIEGO , Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC
12:48pm, Thursday, 22'nd Dec 2022
The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.
Why Is Mirati Therapeutics (MRTX) Stock Up Today?
12:27pm, Thursday, 22'nd Dec 2022
Mirati Therapeutics (NASDAQ: MRTX ) stock is rising on Thursday as investors react to a special designation from the FDA. This has the FDA granting Breakthrough Therapy Designation (BTD) to Mirati The
2 Biotech Stocks Making Headlines
10:42am, Thursday, 22'nd Dec 2022
Two biotech stocks are in the spotlight today, ProQR Therapeutics NV (NASDAQ:PRQR) and Mirati Therapeutics Inc (NASDAQ:MRTX), with the former attracting plenty of options activity.
Mirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug
08:42am, Thursday, 22'nd Dec 2022
Shares of Mirati Therapeutics Inc. MRTX, +0.10% jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Kraza
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.
Mirati's lung cancer drug gets an accelerated approval
09:03am, Tuesday, 13'th Dec 2022
Shares of Mirati Therapeutics Inc. MRTX, -0.81% were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administrati
